Our Magazine
Brussels Morning Online Newspaper
Saturday, January 23, 2021
No Result
View All Result
  • Home
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
  • Home
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Online Newspaper
No Result
View All Result
Home Europe

UK regulator prepares for Astrazeneca vaccine

Sophia Akram by Sophia Akram
27 November 2020
in Europe
UK regulator prepares for Astrazeneca vaccine

In this photo illustration the medical syringe (coronavirus vaccine) is seen with AstraZeneca PLC company logo displayed on a screen in the background

Share on FacebookShare on Twitter

London (Brussels Morning) The UK government has asked its regulator — the Medicines and Healthcare Products Regulatory Agency (MHRA) — to assess the vaccine being developed and licensed by Oxford University and AstraZeneca, respectively, moving one step closer to a national rollout.

The referral to MHRA “marks a significant first step in getting the vaccine approved for deployment”, said the Department of Health and Social Care.

“We have formally asked the regulator to assess the Oxford/AstraZeneca vaccine, to understand the data and determine whether it meets rigorous safety standards”, said Matt Hancock.

Should the vaccine meet safety, efficacy and quality standards, the UK could be one of the first countries to get the vaccine.

A hundred million doses have been preordered, while the MHRA has already been asked to assess the vaccine developed by German American team Pfizer and BioNTech, of which it has ordered 40 million doses.

Pfizer and BioNTech trials have demonstrated its candidate has a 90 percent efficacy, while AstraZeneca and Oxford have had mixed results with an average effectiveness of 70 percent between 62 percent to 90 percent, although they are working on more dependable results, they have said.

Professor David Salisbury, a former Department of Health immunisation director, said to the BBC that the Oxford and Astrazeneca’s low efficacy would mean there would be “tough choices”.

“I think you have to think very carefully what we do with one hundred million doses of a product that isn’t protecting as well as the alternative”, he said, suggesting the vaccines with higher efficacy levels could be reserved for vulnerable or older members of the public.

As a ‘second wave’ of the virus has hit the UK, another national lockdown lasting four weeks is due to end next week.

Scientists have said the R rate in England — the number of people an infected person passes the virus to — has dropped below 1 to around 0.9. That means for every 10 people with COVID-19, they will pass it on to 9 or 10 people.

The country will move into a new phase of tiered restrictions, according to the local infection rate, with a limited five-day concession over Christmas so family members can see each other over the holidays.

Tags: Astrazeneca vaccineMain-SliderUK government
Sophia Akram

Sophia Akram

Sophia Akram is the Brussels Morning London correspondent. Based in London, Sophia is a journalist with a portfolio rich in human rights, politics and foreign policy coverage, plus extensive experience in Europe, the Middle East and Asia.

Latest post

Ombudsman launches investigation into Commission’s COVID-19 vaccine contracts

Ombudsman launches investigation into Commission’s COVID-19 vaccine contracts

10 hours ago
Fears violence will return to Iraq ahead of elections

Fears violence will return to Iraq ahead of elections

10 hours ago

Most Read

  • Italy’s cannabis industry could rival the legal market in the US

    Italy’s cannabis industry could rival the legal market in the US

    0 shares
    Share 0 Tweet 0
  • Can Armenia and Azerbaijan win peace together?

    0 shares
    Share 0 Tweet 0
  • How Emiratis shape the European defense agenda

    0 shares
    Share 0 Tweet 0
  • How EU trade and investment deals can fight climate change

    0 shares
    Share 0 Tweet 0
  • The groundbreaking significance of the EU’s European Public Prosecutor’s Office

    0 shares
    Share 0 Tweet 0

Subscribe
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.